Base de dados : MEDLINE
Pesquisa : D23.050.327.495.500.475 [Categoria DeCS]
Referências encontradas : 18387 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1839 ir para página                         

  1 / 18387 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384977
[Au] Autor:Zou DM; Rong DD; Zhao H; Su L; Sun WL
[Ad] Endereço:Department of Hematology.
[Ti] Título:Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report.
[So] Source:Medicine (Baltimore);96(52):e9566, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: This report describes seroconversion of hepatitis B surface antigen (HBsAg) in a patient with marked iron overload caused by chronic hepatitis B (CHB) after receiving iron chelation therapy and discusses the role of iron chelation therapy in CHB. PATIENT CONCERNS: Increased serum ferritin level for 2 months. DIAGNOSIS: Secondary iron overload and CHB. INTERVENTION: To relieve iron load of the body, the patient underwent regular phlebotomy therapy and deferoxamine (DFO) therapy. During the therapy, serum ferritin and hepatitis B virus (HBV) were monitored and the iron concentration of the liver and heart were followed by T2* of magnetic resonance imaging (MRI) scan. OUTCOMES: Serum ferritin gradually decreased. Approximately 1 year after the therapy, HBsAg turned persistently negative. LESSONS: Iron chelation therapy may attenuate HBV infection.
[Mh] Termos MeSH primário: Terapia por Quelação/métodos
Desferroxamina/uso terapêutico
Hepatite B Crônica/complicações
Sobrecarga de Ferro/complicações
Sobrecarga de Ferro/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Ferritinas/sangue
Antígenos de Superfície da Hepatite B/imunologia
Seres Humanos
Sobrecarga de Ferro/terapia
Masculino
Flebotomia/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 9007-73-2 (Ferritins); J06Y7MXW4D (Deferoxamine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009566


  2 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29198036
[Au] Autor:Hara J; Tanaka Y; Kaneko H; Itoh Y; Ikegaya H
[Ad] Endereço:Department of Forensic Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo, Kyoto, 602-8566, Japan.
[Ti] Título:Detection of hepatitis B virus DNA and HBsAg from postmortem blood and bloodstains.
[So] Source:Arch Virol;163(3):633-637, 2018 Mar.
[Is] ISSN:1432-8798
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:A large number of accidental virus infections occur in medical and non-medical workers exposed to infectious individuals and materials. We evaluated whether postmortem blood and bloodstains containing hepatitis B virus (HBV) are infectious. HBV-infected blood and bloodstains were stored for up to 60 days at room temperature and subsequently screened for hepatitis B surface antigen (HBsAg) and HBV DNA. In addition, HBV-positive postmortem blood was added to a cell line and the production of HBV virions was examined over a period of 7 days. HBsAg and HBV DNA were detected in all samples stored for 60 days at room temperature. HBV-positive postmortem blood successfully infected the cell line and progeny viruses were produced for up to 6 days. Thus, it is crucial that due care is taken when handling not only living material infected with HBV, as well as other harmful viruses, but also blood or body fluids from cadavers or medical waste.
[Mh] Termos MeSH primário: DNA Viral/sangue
Anticorpos Anti-Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/isolamento & purificação
Hepatite B/sangue
[Mh] Termos MeSH secundário: Autopsia
Preservação de Sangue
Feminino
Células Hep G2
Hepatite B/prevenção & controle
Hepatite B/transmissão
Hepatite B/virologia
Vírus da Hepatite B/genética
Vírus da Hepatite B/imunologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171204
[St] Status:MEDLINE
[do] DOI:10.1007/s00705-017-3665-x


  3 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29315352
[Au] Autor:Bivigou-Mboumba B; Amougou-Atsama M; Zoa-Assoumou S; M'boyis Kamdem H; Nzengui-Nzengui GF; Ndojyi-Mbiguino A; Njouom R; François-Souquière S
[Ad] Endereço:Unité Mixte de Recherches VIH et Maladies Infectieuses Associées (UMR VIH-MIA), Centre International de Recherches Médicales (CIRMF), Libreville, Gabon.
[Ti] Título:Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
[So] Source:PLoS One;13(1):e0190592, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA). We used Monolisa HBsAg ULTRA, Anti-HBc Plus and Anti-HBs Plus EIA kits for serological analyses. HBV DNA viral load (HBV DNA VL) was determined by real time PCR and molecular characterization of HBV strains was performed by sequencing and phylogenetic analysis of partial HBV surface and core genes. At all, 70.2% of patients were under antiretroviral therapy. The prevalence of HBsAg was 8.8% (43/487). Detectable HBV DNA was found in 69.7% (30/43) of HBsAg positive patients and in 17.5% (24/137) HBsAg negative patients. HBV DNA VL was significantly higher among patient with CD4 cell counts less than 200 cells/mm3 than those with CD4 cell counts greater than 500 cells/mm3 (p = 0.008). We confirmed the presence of HBV sub-genotypes QS-A3 (40%), and A4 (20%) and HBV-E genotype (40%). The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif. Occult hepatitis B infection (OBI) was found in patients with isolated HBcAb and among patients who had completed their HBsAg seroconversion. We detected HBV DNA for one patient without any HBV serological marker. This study provides a new landmark for the comprehension of HBV infection in PLHA in urban areas. OBI enhances HBV DNA prevalence and should be investigated in all HBsAg negative individuals.
[Mh] Termos MeSH primário: DNA Viral/isolamento & purificação
Infecções por HIV/complicações
Vírus da Hepatite B/genética
Hepatite B/complicações
[Mh] Termos MeSH secundário: Adolescente
Adulto
Contagem de Linfócito CD4
Feminino
Gabão/epidemiologia
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/imunologia
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Carga Viral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190592


  4 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29296152
[Au] Autor:Breakwell L; Tevi-Benissan C; Childs L; Mihigo R; Tohme R
[Ad] Endereço:Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
[Ti] Título:The status of hepatitis B control in the African region.
[So] Source:Pan Afr Med J;27(Suppl 3):17, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:The World Health Organization (WHO) African Region has approximately 100 million people with chronic hepatitis B virus (HBV) infection. This review describes the status of hepatitis B control in the Region. We present hepatitis B vaccine (HepB) coverage data and from available data in the published literature, the impact of HepB vaccination on hepatitis B surface antigen (HBsAg) prevalence, a marker of chronic infection, among children, HBsAg prevalence in pregnant women, and risk of perinatal transmission. Lastly, we describe challenges with HepB birth dose (HepB-BD) introduction reported in the Region, and propose strategies to increase coverage. In 2015, regional three dose HepB coverage was 76%, and 16(34%) of 47 countries reported ≥ 90% coverage. Overall, 11 countries introduced HepB-BD; only nine provide universal HepB-BD, and of these, five reported ≥ 80% coverage. From non-nationally representative serosurveys among children, HBsAg prevalence was lower among children born after HepB introduction compared to those born before HepB introduction. However, some studies still found HBsAg prevalence to be above 2%. From limited surveys among pregnant women, the median HBsAg prevalence varied by country, ranging from 1.9% (Madagascar) to 16.1% (Niger); hepatitis B e antigen (HBeAg) prevalence among HBsAg-positive women ranged from 3.3% (Zimbabwe) to 28.5% (Nigeria). Studies in three countries indicated that the risk of perinatal HBV transmission was associated with HBeAg expression or high HBV DNA viral load. Major challenges for timely HepB-BD administration were poor knowledge of or lack of national HepB-BD vaccination guidelines, high prevalence of home births, and unreliable vaccine supply. Overall, substantial progress has been made in the region. However, countries need to improve HepB3 coverage and some countries might need to consider introducing the HepB-BD to help achieve the regional hepatitis B control goal of < 2% HBsAg prevalence among children < 5 years old by 2020. To facilitate HepB-BD introduction and improve timely coverage, strategies are needed to reach both facility-based and home births. Strong political commitment, clear policy recommendations and staff training on HepB-BD administration are also required. Furthermore, high quality nationally representative serosurveys among children are needed to inform decision makers about progress towards the regional control goal.
[Mh] Termos MeSH primário: Vacinas contra Hepatite B/administração & dosagem
Hepatite B Crônica/prevenção & controle
Vacinação/estatística & dados numéricos
[Mh] Termos MeSH secundário: África/epidemiologia
Criança
Feminino
Antígenos de Superfície da Hepatite B
Antígenos E da Hepatite B
Hepatite B Crônica/epidemiologia
Seres Humanos
Transmissão Vertical de Doença Infecciosa/prevenção & controle
Gravidez
Complicações Infecciosas na Gravidez/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 0 (Hepatitis B Vaccines); 0 (Hepatitis B e Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.supp.2017.27.3.11981


  5 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27776593
[Au] Autor:Iglecias LM; Puga MA; Pompílio MA; Teles SA; Croda J; Lima LA; Lago BV; Martins RM; Motta-Castro AR
[Ad] Endereço:Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
[Ti] Título:Epidemiological study of hepatitis B virus among prisoners with active tuberculosis in Central Brazil.
[So] Source:Int J Tuberc Lung Dis;20(11):1509-1515, 2016 Nov.
[Is] ISSN:1815-7920
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to environmental and social conditions inherent to incarceration, tuberculosis (TB) and hepatitis B virus (HBV) are major diseases among prison inmates. OBJECTIVE: To determine overall and occult HBV infection (OBI) prevalence rates, risk factors and genotype distribution among inmates with active TB. STUDY DESIGN: A cross-sectional study was conducted among 216 inmates with active TB recruited at the largest prisons in Campo Grande, Mato Grosso do Sul, Central Brazil. The participants were interviewed and tested for the presence of serological markers for HBV infection. RESULTS: The overall prevalence of HBV infection (total hepatitis B core antibodies) was 10.2% (95%CI 6.2-14.2). HBV surface antigen (HBsAg) prevalence was 1.4% (3/216). HBV DNA was detected in all three HBsAg-positive samples and in 10.5% (2/19) of the anti-HBc-positive samples (OBI), giving a HBV-TB co-infection prevalence of 2.3% (5/216). A multivariate analysis of risk factors showed that history of sharing cutting instruments, length of incarceration and homosexual sex were associated with HBV infection. CONCLUSION: Our findings indicate that HBV remains an important public health concern among prison inmates and active TB-HBV co-infection needs to be addressed for effective treatment.
[Mh] Termos MeSH primário: Coinfecção/epidemiologia
Hepatite B/epidemiologia
Prisioneiros
Tuberculose/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Brasil/epidemiologia
Coinfecção/diagnóstico
Estudos Transversais
DNA Viral/isolamento & purificação
Estudos Epidemiológicos
Feminino
Hepatite B/diagnóstico
Anticorpos Anti-Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Prevalência
Fatores de Risco
Fatores Socioeconômicos
Tuberculose/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  6 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384914
[Au] Autor:Zhang L; Xie XY; Chen Y; Ge NL; Chen RX; Gan YH; Zhang BH; Wang YH; Ren ZG
[Ad] Endereço:Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China.
[Ti] Título:Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads.
[So] Source:Medicine (Baltimore);96(52):e9377, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Radiofrequency ablation (RFA) is a first-line option for the treatment of small liver cancers, but the recurrence remains a problem affecting long-term survival. Hepatitis B virus (HBV) activity is associated with the prognosis of hepatocellular carcinoma (HCC). We investigated the significance of hepatitis B surface antigen (HBsAg) in HCC recurrence after curative RFA treatment in HBV-related small HCC.We enrolled 404 HBV-related patients with small HCC (≤3 cm) who underwent curative RFA. We used univariate and multivariate analyses to investigate the baseline levels of HBsAg, in addition to other known risk factors for HCC recurrence, for association with HCC tumor recurrence after curative RFA.The overall 1-, 2-, and 3-year recurrence-free survival (RFS) rates were 75%, 50%, and 34%, respectively. The median recurrence-free time was 25 months. The level of HBsAg was an independent risk factor for recurrence in patients with lower HBV-DNA levels. In hepatitis Be antigen (HBeAg)-negative patients, the 1-, 2-, and 3-year RFS rates were 79%, 64%, and 44%, respectively, for that with low HBsAg levels, compared with 73%, 50%, and 37%, respectively, for that with high HBsAg levels (P = .039).HBsAg might serve as a valuable marker to evaluate the risk of HCC recurrence in HBeAg-negative patients with low HBV viral load.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/sangue
Carcinoma Hepatocelular/cirurgia
Antígenos de Superfície da Hepatite B/sangue
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/cirurgia
Recidiva Local de Neoplasia/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Hepatocelular/virologia
Ablação por Cateter
Feminino
Vírus da Hepatite B
Seres Humanos
Neoplasias Hepáticas/virologia
Masculino
Meia-Idade
Recidiva Local de Neoplasia/virologia
Estudos Retrospectivos
Carga Viral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009377


  7 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29307521
[Au] Autor:Han W; Ni Q; Liu K; Yao Y; Zhao D; Liu X; Chen Y
[Ad] Endereço:Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, 79 Qingchun Road, Hangzhou 310003, China.
[Ti] Título:Decreased CD122 on CD56 NK associated with its impairment in asymptomatic chronic HBV carriers with high levels of HBV DNA, HBsAg and HBeAg.
[So] Source:Life Sci;195:53-60, 2018 Feb 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: NK cells play important roles in inhibiting HBV replication and preventing HBV infection. However, NK-cell dysfunction has not been fully studied in asymptomatic chronic HBV carriers (ASC). This study aims to assess decreased expression of CD122 associated with impaired NK cells and the restoration of NK cells with IL-2 and IL-15 stimulation. MAIN METHODS: The experiments were performed by flow cytometer, cytotoxicity assay, ELISA and western blotting. KEY FINDINGS: The reduced CD122 on CD56 NK cells and CD56 NK cells is associated with high levels of HBV DNA, HBsAg or HBeAg in ASCs, in which CD56 NK-cell impairment is observed. Moreover, decreased IFN-γ and degranulation and low cytotoxicity by CD56 NK cells after CD122 blockade were revealed. IL-2 and/or IL-15 can restore impaired CD56 NK cells, together with increased p-STAT5, which can be reversed by CD122 blockade. Additionally, IL-2 or IL-15 can enhance IFN-α2-activated CD56 NK-cell immune responses via up-regulating interferon alpha and beta receptor subunit 2 (IFNAR2). SIGNIFICANCE: Down-regulated CD122 on CD56 NK cell in ASCs with massive viral antigens and high viremia is associated with its impairment, which can be restored by IL-2 and/or IL-15, or combined with IFN-α2.
[Mh] Termos MeSH primário: Antígeno CD56/biossíntese
DNA Viral/biossíntese
Antígenos de Superfície da Hepatite B/sangue
Antígenos E da Hepatite B/sangue
Vírus da Hepatite B/metabolismo
Hepatite B/metabolismo
Subunidade beta de Receptor de Interleucina-2/biossíntese
Células Matadoras Naturais/metabolismo
[Mh] Termos MeSH secundário: Adulto
Antígeno CD56/genética
Portador Sadio
DNA Viral/genética
Feminino
Vírus da Hepatite B/genética
Seres Humanos
Interferon gama/biossíntese
Interleucina-15/farmacologia
Interleucina-2/farmacologia
Subunidade beta de Receptor de Interleucina-2/genética
Masculino
Receptor de Interferon alfa e beta/biossíntese
Receptor de Interferon alfa e beta/genética
Fator de Transcrição STAT5/biossíntese
Fator de Transcrição STAT5/genética
Viremia/sangue
Viremia/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD56 Antigen); 0 (DNA, Viral); 0 (Hepatitis B Surface Antigens); 0 (Hepatitis B e Antigens); 0 (IFNAR2 protein, human); 0 (Interleukin-15); 0 (Interleukin-2); 0 (Interleukin-2 Receptor beta Subunit); 0 (STAT5 Transcription Factor); 156986-95-7 (Receptor, Interferon alpha-beta); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE


  8 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262514
[Au] Autor:Chen JG; Zhang YH; Zhu J; Lu JH; Wang JB; Sun Y; Xue XF; Lu LL; Chen YS; Wu Y; Jiang XP; Ding LL; Zhang QN; Zhu YR
[Ad] Endereço:Department of Etiology, Qidong Liver Cancer Institute, 226200 Qidong, China.
[Ti] Título:[Early diagnosis and early treatment for liver cancer in Qidong: survival of patients and effectiveness of screening].
[So] Source:Zhonghua Zhong Liu Za Zhi;39(12):946-951, 2017 Dec 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To evaluate the patients' survival and effectiveness of the live cancer screening for population at high risk for liver cancer in Qidong. According to the Expert Scheme proposed the Expert Committee of Early Detection and Early Treatment, China Cancer Foundation, diagnostical screening by using combined methods of alpha-fetoprotein and B ultrasound monitoring were carried out biannually in individuals with positive HBsAg who were screened from Qidong area. The evaluation indices of the effectiveness are task completion rate of screening, detection rate of liver cancer, early diagnosis rate, and treatment rate. The deadline of the follow-up for the surviving outcome was March 31, 2016. The life-table method was used to calculate the observed survival, and to make comparison and significant tests between survival rates in Group A (those found via repeated periodic screening) and Group B (those diagnosed without periodic screening). Since 2007, 38 016 target population have been screened, and 3 703(9.74%) individuals with positive HBsAg were found. Except for 29 patients with liver cancer at the initial screening, 3 674 persons in the cohort were followed up; 268 patients with liver cancer were detected from the 33 199 person-times screening, with an annual detection rate of 1.61%. Of them, 186 patients were found in Group A(1.12%), in which 149 patients were the early cases, with an early detection rate of 80.11%; 167 out of 186(89.78%) patients received treatment after diagnosis. The incidence of liver cancer in this HBsAg (+ ) cohort of 25 452 person-years was 1 052.96 per 100 000 annually, 187 cases in males(1 488.45/100 000)and 81 cases in females(628.46/100 000). The 1-, 3-, 5-, and 8-year survival of all patients with liver cancer were 64.55%, 40.50%, 32.54%, and 19.65%, respectively. The 1-, 3-, 5-, and 8-year survival rates were 77.16%, 49.04%, 38.53%, and 24.25% in Group A, and were 36.25%, 21.21%, 21.21%, and 0% in Group B, respectively, with significant differences between two groups ( <0.05). The findings show that screening of individuals at high-risk of development of liver cancer, with semiannual AFP and B ultrasound, according to the Expert Scheme, is effective not only in increasing detection rate but also in detecting liver cancer at early stage, and in improving patients' survival as well.
[Mh] Termos MeSH primário: Detecção Precoce de Câncer
Antígenos de Superfície da Hepatite B/sangue
Neoplasias Hepáticas/diagnóstico
Neoplasias Hepáticas/terapia
[Mh] Termos MeSH secundário: China/epidemiologia
Estudos de Coortes
Feminino
Seres Humanos
Incidência
Neoplasias Hepáticas/epidemiologia
Neoplasias Hepáticas/mortalidade
Masculino
Distribuição por Sexo
Taxa de Sobrevida
Ultrassonografia
alfa-Fetoproteínas/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 0 (alpha-Fetoproteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2017.12.013


  9 / 18387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457830
[Au] Autor:Costa JEF; Morais VMS; Gonçales JP; Silva DM; Coêlho MRCD
[Ad] Endereço:Health Sciences Center, Federal University of Pernambuco, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50670-901, Recife, Pernambuco, Brazil. Electronic address: joanne_ferraz@yahoo.com.br.
[Ti] Título:Prevalence and risk factors for hepatitis B and C viruses in patients with leprosy.
[So] Source:Acta Trop;172:160-163, 2017 Aug.
[Is] ISSN:1873-6254
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:It has been reported a higher seroprevalence of HBV and HCV in leprosy patients than in the general population, but the reasons for these findings are not yet clear. On the other hand, there is evidence that these viruses may influence the onset of leprosy reactional episodes, an important cause of neurological sequelae. This study aimed to determine seroprevalence and risk factors for HBV and HCV in leprosy patients and to investigate its association with leprosy reactions. Patients attended from 2015 to 2016 at a Reference Center in Leprosy in Northeastern region of Brazil, were interviewed, had their records reviewed to investigate biological, clinical, behavioral and socioeconomic factors, and underwent blood sample collection. Biological samples were tested for HBV (HBsAg, anti-HBs and anti-HBs) and HCV (anti-HCV) serological markers by ELISA and, in anti-HCV positive samples, HCV RNA was screened by real time PCR. SPSS program was used to analyze the data. A total of 403 leprosy patients were included. Although anti-HBc was positive in 14.1%, there was no detection of HBsAg, which contradicts the hypothesis that leprosy patients have immune deficit that make them more prone to chronic HBV infection. Multibacillary leprosy (0.057), health-related work (0.011) and lower educational level (0.035) were associated with anti-HBc positivity. Anti-HCV was positive in 0.5%, with no detection of HCV RNA. No association was identified between anti-HCV and the epidemiological analyzed factors. There was also no association of anti-HBc or anti-HCV with type 1 or type 2 leprosy reactions. Thus, the seroprevalence of HBV and HCV in leprosy patients was similar to that of the general population of Northeastern region of Brazil, and no association of HBV or HCV with leprosy reactions was observed.
[Mh] Termos MeSH primário: Hepatite B/complicações
Hepatite B/virologia
Hepatite C/complicações
Hepatite C/virologia
Hanseníase/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/sangue
Brasil/epidemiologia
Ensaio de Imunoadsorção Enzimática
Feminino
Hepacivirus/isolamento & purificação
Anticorpos Anti-Hepatite B
Antígenos de Superfície da Hepatite B
Vírus da Hepatite B/isolamento & purificação
Anticorpos Anti-Hepatite C
Seres Humanos
Hanseníase/virologia
Masculino
Meia-Idade
Prevalência
Reação em Cadeia da Polimerase em Tempo Real
Fatores de Risco
Estudos Soroepidemiológicos
Testes Sorológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens); 0 (Hepatitis C Antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  10 / 18387 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Lampe, Elisabeth
Texto completo SciELO Brasil
[PMID]:29211108
[Au] Autor:Portilho MM; Nabuco LC; Villela-Nogueira CA; Brandão-Mello CE; Pilotto JH; Flores GL; Lewis-Ximenez LL; Lampe E; Villar LM
[Ad] Endereço:Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Hepatites Virais, Rio de Janeiro, RJ, Brasil.
[Ti] Título:Detection of occult hepatitis B in serum and oral fluid samples.
[So] Source:Mem Inst Oswaldo Cruz;113(1):62-65, 2018 Jan.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:In occult hepatitis B infection (OBI), hepatitis B virus DNA (HBV DNA) can be detected in serum samples; however, oral fluid collection for detection of HBV DNA has not yet been explored, despite the availability of collection devices. Serum and oral fluid samples from 45 hepatitis B core antibody (anti-HBc)-positive patients were collected for the amplification of the HBV polymerase gene. HBV DNA was detected in five serum and four oral fluid samples (the detection limit for oral fluid was 1.656 log IU/mL in paired serum). In conclusion, simple methodologies of sample collection and in-house polymerase chain reaction (PCR) allowed detection of HBV DNA, and these could be used to improve the diagnosis of OBI, especially in locations with limited resources.
[Mh] Termos MeSH primário: DNA Viral/análise
Anticorpos Anti-Hepatite B/análise
Antígenos de Superfície da Hepatite B/análise
Vírus da Hepatite B/genética
Hepatite B/diagnóstico
Saliva/virologia
[Mh] Termos MeSH secundário: Adulto
Idoso
DNA Viral/sangue
Feminino
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Reação em Cadeia da Polimerase
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE



página 1 de 1839 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde